Childhood vs. juvenile absence epilepsy: How to make a diagnosis.


Journal

Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 03 09 2022
revised: 28 09 2022
accepted: 05 10 2022
pubmed: 13 10 2022
medline: 8 11 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

We tried to differentiate childhood absence epilepsy (CAE) from juvenile absence epilepsy (JAE) based on their clinical characteristics. We planned to identify a cutoff point for the age at onset of seizures between CAE and JAE that is able to reliably predict the presence of generalized tonic-clonic seizures (GTCS) (that has important implications for treatment strategy and outcome prediction). This was a retrospective database study. All patients with an electro-clinical diagnosis of CAE or JAE were studied at the outpatient epilepsy clinic at Shiraz University of Medical Sciences, Shiraz, Iran, from 2008 until 2022. The receiver operating characteristic (ROC) curve was used for the statistical analysis to predict a cutoff point for the age at onset of seizures between the syndromes. One hundred and ninety-six patients were studied. Generalized tonic-clonic seizure was reported by 134 patients (68.4%). The ROC curve of the age at seizure onset was an acceptable indicator to anticipate GTCS; the best cutoff point was at 9.65 years; 87 patients (44.4%) had CAE and 109 people (55.6%) had JAE. The odds ratio of the presence of GTCS in JAE compared with CAE was 3.6. Syndrome diagnosis of CAE vs. JAE has important practical implications. The age at onset of seizures serves as a reliable and meaningful variable to differentiate CAE from JAE.

Identifiants

pubmed: 36223676
pii: S1059-1311(22)00233-3
doi: 10.1016/j.seizure.2022.10.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-128

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Disclosure statement Ali A. Asadi-Pooya: Honoraria from Cobel Daruo, Tekaje, Sanofi, and RaymandRad; Royalty: Oxford University Press (Book publication); Grant from the National Institute for Medical Research Development. Mohsen Farazdaghi: no conflict of interest.

Auteurs

Ali A Asadi-Pooya (AA)

Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: aliasadipooya@yahoo.com.

Mohsen Farazdaghi (M)

Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH